Main difference between Ozempic and game-changing 2.0 version explained as studies show it could 'transform' the industry
It was only a matter of a time before a new one joined the market
There is a main difference between Ozempic and a game changing 2.0 version that has been explained as studies show it has the potential to completely ‘transform’ the industry.
With GLP-1 drugs taking the weight loss industry by storm, it was only a matter of a time before a new one joined the market.
Celebrities including the likes of Kelly Clarkson and Sharon Osbourne have shared their successes from taking weight loss injections such as Ozempic and Mounjaro.
Now though, there could be a new drug on the market that might completely change the game.
Advert
This is because this new medication comes in the form of a pill rather than an injection.
In September, Eli Lilly, the manufacturer of Mounjaro, announced that it planned to develop a daily pill named Orforglipron.
If approved by the FDA, both Novo Nordisk and Eli Lilly intend to launch once-a-day weight loss pills by next year, which would not require refrigeration, already cutting costs from transporting injectable medications.
What have experts said?
David Lau, who is an endocrinologist and professor emeritus at the University of Calgary Cumming School of Medicine, explained: “With this newer generation of medications, we’re not just focusing on weight loss. We’re talking about changes beyond what you see on the scale.”
He further pointed out the increase in accessibility, adding: “Some people are afraid of using needles and giving themselves injections.”
Meanwhile, Sean Wharton, who is a physician in Toronto and the lead author of key papers on oral GLP-1 drugs published in September, pointed out: “What Henry Ford did with the car wasn’t to make a better car. He just made more of them and made them more accessible.”
Eli Lilly Chief Scientific Officer Dan Skovronsky said of their upcoming pill: “For the majority of patients, this could be the main medicine that they need to control their Type 2 diabetes as well as their obesity.”
In a statement provided to LADbible Group, a spokesperson for Novo Nordisk said: “We are working closely with the FDA to ensure we can bring Wegovy® in a pill (oral semaglutide), the first oral GLP-1 RA for obesity, to the US early next year. In addition, in September 2025, Novo Nordisk submitted oral semaglutide 25 mg to the EMA. Pending approval, Novo Nordisk is considering launching oral semaglutide 25 mg in select EU markets.”
LADbible Group has contacted Eli Lilly for a comment.